Home / Issues / Issue #4
Psyche Insights Weekly · Issue #4

A psilocin drug passes its first Phase 3, the FDA's fast lane for psilocybin is in doubt, and Czechia's first psilocybin patients slip to 2027

· Published by Psyche Vibes Ltd, London

Independent, evidence-first news on psychedelic-assisted therapy research, regulation and business, with the UK and Europe first. This is information, not medical advice. We do not promote using any controlled substance outside lawful clinical settings.

Another psychedelic drug candidate has passed a Phase 3 trial, and its next pivotal study is recruiting in the UK and five EU countries. In the US, the fast-track scheme meant to speed the two psilocybin reviews may have been shelved. In Europe, Czechia's first psilocybin patients look set to wait until 2027, and a new initiative wants countries to stop building early-access schemes from scratch. Every claim links to its source, and our live approval tracker is updated.


💊 Trials: a psilocin drug passes Phase 3

  • Helus's HLP003 meets its primary endpoint. On 16 November, Helus Pharma (formerly Cybin) said its Phase 3 APPROACH trial of HLP003, a deuterated form of psilocin (the active form of psilocybin), met its primary endpoint. The trial had 222 adults with moderate to severe major depression who stayed on their antidepressant. At week 6, depression scores (MADRS) fell 7.6 points more than with placebo, and 7.0 points more at week 12. The company reported three treatment-related serious adverse events (Helus, 16 Nov). BioSpace reports these were two cases of depression and one suicide attempt, the last in a participant who had not responded, 55 days after the second dose (BioSpace, 16 Nov).
  • The second Phase 3 recruits in Europe. Helus expects results from EMBRACE, its second pivotal trial, in the fourth quarter of 2027 (same Helus source). ClinicalTrials.gov lists EMBRACE as recruiting, with sites in the UK, Czechia, Germany, Greece, Ireland and Poland (NCT06793397). It is in our directory.
  • A small MDMA pilot in veterans with PTSD and alcohol problems. Brown University researchers reported an open-label pilot of MDMA-assisted therapy in US veterans with both PTSD and alcohol use disorder. Nine of the 10 people enrolled completed it, PTSD scores (CAPS-5) fell by more than 22 points on average and no serious adverse events were reported. There was no control group, and the researchers say the drop in drinking was not clinically significant. A larger randomised trial with the Providence VA Medical Center is under way (Brown University via Medical Xpress, 17 Nov; Alcohol, 2026).
  • Dublin's GH Research gets early FDA feedback. On 13 November, GH Research said the FDA gave "positive initial feedback" on its planned pivotal programme for GH001, inhaled mebufotenin (5-MeO-DMT), in treatment-resistant depression. The plan uses one fixed dose per visit from a new aerosol device. The design is not final: an End-of-Phase 2 meeting is expected in early 2027, with the pivotal trials to start shortly after. A pivotal programme in postpartum depression is targeted for the second half of 2027 (GH Research, 13 Nov).

🇬🇧 UK: a trial designed to fix the blinding problem

  • King's College London opens SLEEPY. The study tests whether psilocybin can be timed to act while people sleep, so they are less sure whether they had the drug or a placebo. That is a known weak point of psychedelic trials. It recruits healthy adults aged 18 to 65 who are not on psychotropic medication and have used psilocybin before. Recruitment runs from November 2026 to May 2028. After three set-up stages, 16 people will take psilocybin and a placebo four weeks apart (King's College London; ISRCTN10648713). It is a method study, not a treatment, and it is listed in our UK trials guide.
  • The law has not changed. Psilocybin remains in Schedule 1. The Home Office has said that reconsidering this "would ordinarily follow" an MHRA licence assessment (written answer 37245).

🇪🇺 Europe: waiting in Czechia, a Swiss explainer

  • Czechia's first psilocybin patients may wait until 2027. Psilocybin has been a legal treatment for defined forms of depression in Czechia since January, but nobody has yet been treated outside trials. On 18 November, a psychologist who works on psilocybin trials at the National Institute of Mental Health (NUDZ) told Flowee that treating the first patients in 2027 is realistic. She said the substance is hard to obtain and the system for insurers to cover treatment is still being set up (Flowee, 18 Nov, in Czech). NUDZ had previously pointed to the second half of 2026 (NUDZ; our Czechia guide).
  • A European plan for early access. On 16 November, the Swedish non-profit Norrsken Mind said it is funding the first phase of a European Early Access Coordination Initiative, run by the OPEN Foundation and the Psychedelic Access and Research European Alliance (PAREA). Early access routes, such as compassionate use, let a national regulator allow a medicine before it has a marketing authorisation. Only a few European countries have such schemes for psychedelic therapy, each built separately. The initiative plans to map the legal routes, share documents from past applications and work towards common real-world data collection (Norrsken Mind, 16 Nov). Germany's programme is explained in our Germany guide.
  • New guide: psychedelic therapy in Switzerland. Our new explainer, Psychedelic therapy in Switzerland, covers how the federal "limited medical use" licences work: they are for Swiss residents only and are applied for by the treating doctor. It also sets out how many are issued and what basic health insurance does and does not pay for. It is not a guide to travelling for treatment.
  • New guide: psychedelic trials recruiting in Europe. Our second new guide lists the psilocybin, MDMA, LSD and ketamine studies that the EU register, ClinicalTrials.gov and ISRCTN show as recruiting, by country, with the registry checked on 19 November. Only the study team can decide who is eligible.

Read the rest free: subscribe

3 more sections in this issue. Subscribers get every issue in full, free, each week.

Subscribe free →
Already subscribed? The full issue is in your inbox. One email a week, unsubscribe any time, and we never sell your data.

Psyche Insights is an independent publication by Psyche Vibes Ltd, 71-75 Shelton Street, Covent Garden, London WC2H 9JQ. Nothing here is medical, legal or investment advice. If you're struggling, speak to your GP or call Samaritans on 116 123 (UK). Sponsorships are always labelled. Spotted an error? Email [email protected] and we'll correct it publicly.